I founded ENLIGHTEN SCIENTIFIC in early 2017. After 24-years of working in the pharmaceutical industry I decided to retire from the only company I had worked for — GlaxoSmithKline. I began my GSK career in 1993 working on the Phase III formulation and device development of metered-dose inhalers (MDIs). This is one of the most — if not the most — complex delivery platforms. In the early 2000’s I became the CMC leader for one of GSK’s new block-buster MDI products for the North American market — ADVAIR® HFA Inhalation Aerosol — and a key technical contributor to the life cycle management of its Rest of World equivalent — Seretide® MDI. I steered the product through NDA submission and, through my various areas of expertise, the product was approved in mid-2006.
Following launch, I remained within Product Development but became increasingly involved in life-cycle maintenance of not only ADVAIR but other MDI products manufactured globally including Ventolin® HFA Inhalation Aerosol.
During my time with GSK, I learned a tremendous amount about product development and manufacturing, and my own differentiating skills.
Prior to my career with GSK, I invented Phase Analysis Light Scattering (PALS). This is the now the de facto method for measuring zeta potential of dilute colloidal dispersions. Various versions of it are sold by most manufacturers of commercial instruments including Malvern Panalytical, Brookhaven Instruments Corporation, Wyatt Technologies, and Entegris PSS.
In 2018, I developed the Next Generation Electrophoretic Light Scattering system (NG-ELS) that extends PALS to permit measurement of zeta potential of important classes of products that commercial instruments cannot.
I am the foremost authority on the PALS technique.